David Hsiehchen

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors

David Hsiehchen, Mary Katherine Watters, Rong Lü et al. · JAMA Network Open · 2019 · 90 citations · Full text

Pharmacy, Immunology, Oncology +17

Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma

Bernhard Scheiner, Daniel Roessler, Samuel Phen et al. · JHEP Reports · 2022 · 61 citations · Full text

Medicine, Immunology, Oncology +14

Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150

Magdalena Espinoza, Maishara Muquith, Mir Lim et al. · Gastroenterology · 2023 · 52 citations

Medicine, Oncology, Pharmacology +17

Abstract CT003: IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation

Pierce K. H. Chow, Minshan Chen, Ann‐Lii Cheng et al. · Cancer Research · 2023 · 44 citations

Medicine, Oncology, Pharmacology +16